Improving the Tuberculosis Drug Development Pipeline

Chemical Biology and Drug Design

Volumn 86, Issue 5, 2015, Pages 951-960

  Evangelopoulos, Dimitrios ^a   McHugh, Timothy D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biological screening; drug development; gene expression; mechanism based drug design; therapeutic target

Indexed keywords

AMIDE; BEDAQUILINE; ETHAMBUTOL; ISONIAZID; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PRETOMANID; PYRAZINAMIDE; PYRIMIDINE DIMER; QUINOLINE DERIVATIVE; RIFAMPICIN; THIOPHENE; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNIVERSITY; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; PROCEDURES;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84944039139     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12549     Document Type: Article

References (85)

1. WHO (1993) WHO Declares Tuberculosis a Global Emergency. Geneva: World Health Organization.
2. WHO (2014) Global tuberculosis report 2014: WHO report.
3. Udwadia Z.F., (2012) MDR, XDR, TDR tuberculosis: ominous progression. Thorax; 67: 286-288.
4. Pablos-Mendez A., (2000) Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000. Int J Tuberc Lung Dis; 4: 489-490.
5. Zumla A., Nahid P., Cole S.T., (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov; 12: 388-404.
6. Zumla A.I., Gillespie S.H., Hoelscher M., Philips P.P., Cole S.T., Abubakar I., McHugh T.D., Schito M., Maeurer M., Nunn A.J., (2014a) New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis; 14: 327-340.
7. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., et al,. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature; 393: 537-544.
8. Sams-Dodd F., (2005) Target-based drug discovery: is something wrong? Drug Discov Today; 10: 139-147.
9. Guzman J.D., Wube A., Evangelopoulos D., Gupta A., Hufner A., Basavannacharya C., Rahman M.M., Thomaschitz C., Bauer R., McHugh T.D., Nobeli I., Prieto J.M., Gibbons S., Bucar F., Bhakta S., (2011) Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. J Antimicrob Chemother; 66: 1766-1772.
10. Guzman J.D., Evangelopoulos D., Gupta A., Prieto J.M., Gibbons S., Bhakta S., (2012) Antimycobacterials from Lovage Root (Ligusticum officinale Koch). Phytother Res; 27: 993-998.
11. Guzman J.D., Gupta A., Evangelopoulos D., Basavannacharya C., Pabon L.C., Plazas E.A., Munoz D.R., Delgado W.A., Cuca L.E., Ribon W., Gibbons S., Bhakta S., (2010) Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J Antimicrob Chemother; 65: 2101-2107.
12. O'Donnell G., Poeschl R., Zimhony O., Gunaratnam M., Moreira J.B., Neidle S., Evangelopoulos D., Bhakta S., Malkinson J.P., Boshoff H.I., Lenaerts A., Gibbons S., (2009) Bioactive pyridine-N-oxide disulfides from Allium stipitatum. J Nat Prod; 72: 360-365.
13. Osman K., Evangelopoulos D., Basavannacharya C., Gupta A., McHugh T.D., Bhakta S., Gibbons S., (2012) An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis. Int J Antimicrob Agents; 39: 124-129.
14. Kottakota S.K., Benton M., Evangelopoulos D., Guzman J.D., Bhakta S., McHugh T.D., Gray M., Groundwater P.W., Marrs E.C., Perry J.D., Harburn J.J., (2012a) Versatile routes to marine sponge metabolites through benzylidene rhodanines. Org Lett; 24: 6310-6313.
15. Kottakota S.K., Evangelopoulos D., Alnimr A., Bhakta S., McHugh T.D., Gray M., Groundwater P.W., Marrs E.C., Perry J.D., Spilling C.D., Harburn J.J., (2012b) Synthesis and biological evaluation of purpurealidin E-derived marine sponge metabolites: aplysamine-2, aplyzanzine A, and suberedamines A and B. J Nat Prod; 75: 1090-1101.
16. Sim E., Sandy J., Evangelopoulos D., Fullam E., Bhakta S., Westwood I., Krylova A., Lack N., Noble M., (2008) Arylamine N-acetyltransferases in mycobacteria. Curr Drug Metab; 9: 510-519.
17. Amaral L., Boeree M.J., Gillespie S.H., Udwadia Z.F., van Soolingen D., (2010) Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents; 35: 524-526.
18. Amaral L., Viveiros M., (2012) Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents; 39: 376-380.
19. Udwadia Z.F., Sen T., Pinto L.M., (2011) Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov; 6: 88-91.
20. Young D.B., Perkins M.D., Duncan K., Barry C.E. III, (2008) Confronting the scientific obstacles to global control of tuberculosis. J Clin Investig; 118: 1255-1265.
21. Zumla A.I., Schito M., Maeurer M., (2014b) Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines. Lancet Infect Dis; 14: 267-269.
22. Jindani A., (1976) Short-course (6-month) treatment of pulmonary tuberculosis (Second East African/British Medical Research Council Study). Bull Int Union Tuberc; 51: 53-56.
23. Wallis R.S., Kim P., Cole S., Hanna D., Andrade B.B., Maeurer M., Schito M., Zumla A., (2013) Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis; 13: 362-372.
24. van Ingen J., Aarnoutse R.E., Donald P.R., Diacon A.H., Dawson R., Plemper van Balen G., Gillespie S.H., Boeree M.J., (2011) Why do we use 600 mg of Rifampicin in tuberculosis treatment? Clin Infect Dis; 52: e194-e199.
25. Rosenthal I.M., Tasneen R., Peloquin C.A., Zhang M., Almeida D., Mdluli K.E., Karakousis P.C., Grosset J.H., Nuermberger E.L., (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother; 56: 4331-4340.
26. Jindani A., Harrison T.S., Nunn A.J., Phillips P.P., Churchyard G.J., Charalambous S., Hatherill M., et al,. (2014) High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med; 371: 1599-1608.
27. Korbel D.S., Schneider B.E., Schaible U.E., (2008) Innate immunity in tuberculosis: myths and truth. Microbes Infect; 10: 995-1004.
28. van Crevel R., Ottenhoff T.H., van der Meer J.W., (2002) Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev; 15: 294-309.
29. Armstrong J.A., Hart P.D., (1975) Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med; 142: 1-16.
30. Fuller C.L., Flynn J.L., Reinhart T.A., (2003) In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis. Infect Immun; 71: 7023-7034.
31. Rhoades E.R., Cooper A.M., Orme I.M., (1995) Chemokine response in mice infected with Mycobacterium tuberculosis. Infect Immun; 63: 3871-3877.
32. Kim M.J., Wainwright H.C., Locketz M., Bekker L.G., Walther G.B., Dittrich C., Visser A., Wang W., Hsu F.F., Wiehart U., Tsenova L., Kaplan G., Russell D.G., (2010) Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med; 2: 258-274.
33. Russell D.G., Cardona P.J., Kim M.J., Allain S., Altare F., (2009) Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol; 10: 943-948.
34. Tsai M.C., Chakravarty S., Zhu G., Xu J., Tanaka K., Koch C., Tufariello J., Flynn J., Chan J., (2006) Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol; 8: 218-232.
35. Fenhalls G., Stevens L., Moses L., Bezuidenhout J., Betts J.C., van Helden P., Lukey P.T., Duncan K., (2002) In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect Immun; 70: 6330-6338.
36. Marks G.B., Bai J., Simpson S.E., Sullivan E.A., Stewart G.J., (2000) Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med; 162: 1851-1854.
37. Garton N.J., Waddell S.J., Sherratt A.L., Lee S.M., Smith R.J., Senner C., Hinds J., Rajakumar K., Adegbola R.A., Besra G.S., Butcher P.D., Barer M.R., (2008) Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med; 5: e75.
38. Pandey A.K., Sassetti C.M., (2008) Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA; 105: 4376-4380.
39. Mukamolova G.V., Kaprelyants A.S., Young D.I., Young M., Kell D.B., (1998) A bacterial cytokine. Proc Natl Acad Sci USA; 95: 8916-8921.
40. Tufariello J.M., Jacobs W.R. Jr, Chan J., (2004) Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo. Infect Immun; 72: 515-526.
41. Kana B.D., Gordhan B.G., Downing K.J., Sung N., Vostroktunova G., Machowski E.E., Tsenova L., Young M., Kaprelyants A., Kaplan G., Mizrahi V., (2008) The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol; 67: 672-684.
42. Tufariello J.M., Mi K., Xu J., Manabe Y.C., Kesavan A.K., Drumm J., Tanaka K., Jacobs W.R. Jr, Chan J., (2006) Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis. Infect Immun; 74: 2985-2995.
43. Davies A.P., Dhillon A.P., Young M., Henderson B., McHugh T.D., Gillespie S.H., (2008) Resuscitation-promoting factors are expressed in Mycobacterium tuberculosis-infected human tissue. Tuberculosis; 88: 462-468.
44. Mukamolova G.V., Turapov O., Malkin J., Woltmann G., Barer M.R., (2010) Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med; 181: 174-180.
45. Cohen-Gonsaud M., Barthe P., Bagneris C., Henderson B., Ward J., Roumestand C., Keep N.H., (2005) The structure of a resuscitation-promoting factor domain from Mycobacterium tuberculosis shows homology to lysozymes. Nat Struct Mol Biol; 12: 270-273.
46. Kana B.D., Mizrahi V., (2010) Resuscitation-promoting factors as lytic enzymes for bacterial growth and signaling. FEMS Immunol Med Microbiol; 58: 39-50.
47. Keep N.H., Ward J.M., Cohen-Gonsaud M., Henderson B., (2006) Wake up! Peptidoglycan lysis and bacterial non-growth states. Trends Microbiol; 14: 271-276.
48. Cohen N.R., Lobritz M.A., Collins J.J., (2013) Microbial persistence and the road to drug resistance. Cell Host Microbe; 13: 632-642.
49. Keren I., Minami S., Rubin E., Lewis K., (2011) Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio; 2: e00100-e00111.
50. Mitchison D.A., Jindani A., Davies G.R., Sirgel F., (2007) Isoniazid activity is terminated by bacterial persistence. J Infect Dis; 195: 1871-1872; author reply 1872-1873.
51. Mitchison D., Davies G., (2012) The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis; 16: 724-732.
52. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., Pappas F., Phillips P.P., Nunn A.J., (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med; 371: 1577-1587.
53. Wakamoto Y., Dhar N., Chait R., Schneider K., Signorino-Gelo F., Leibler S., McKinney J.D., (2013) Dynamic persistence of antibiotic-stressed mycobacteria. Science; 339: 91-95.
54. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K., (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol; 43: 717-731.
55. Deb C., Lee C.M., Dubey V.S., Daniel J., Abomoelak B., Sirakova T.D., Pawar S., Rogers L., Kolattukudy P.E., (2009) A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE; 4: e6077.
56. Galagan J.E., Minch K., Peterson M., Lyubetskaya A., Azizi E., Sweet L., Gomes A., et al,. (2013) The Mycobacterium tuberculosis regulatory network and hypoxia. Nature; 499: 178-183.
57. Hu Y., Butcher P., Sole K., Mitchison D., Coates A., (1998) Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett; 158: 139-145.
58. Wayne L.G., Hayes L.G., (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun; 64: 2062-2069.
59. Young D., (2009) Animal models of tuberculosis. Eur J Immunol; 39: 2011-2014.
60. De Groote M.A., Gilliland J.C., Wells C.L., Brooks E.J., Woolhiser L.K., Gruppo V., Peloquin C.A., Orme I.M., Lenaerts A.J., (2011) Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother; 55: 1237-1247.
61. Grosset J., Almeida D., Converse P.J., Tyagi S., Li S.Y., Ammerman N.C., Pym A.S., Wallengren K., Hafner R., Lalloo U., Swindells S., Bishai W.R., (2012) Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci USA; 109: 15001-15005.
62. Calderon V.E., Valbuena G., Goez Y., Judy B.M., Huante M.B., Sutjita P., Johnston R.K., Estes D.M., Hunter R.L., Actor J.K., Cirillo J.D., Endsley J.J., (2013) A humanized mouse model of tuberculosis. PLoS ONE; 8: e63331.
63. Jindani A., Aber V.R., Edwards E.A., Mitchison D.A., (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis; 121: 939-949.
64. Wallis R.S., Perkins M.D., Phillips M., Joloba M., Namale A., Johnson J.L., Whalen C.C., Teixeira L., Demchuk B., Dietze R., Mugerwa R.D., Eisenach K., Ellner J.J., (2000) Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med; 161: 1076-1080.
65. Perrin F.M., Lipman M.C., McHugh T.D., Gillespie S.H., (2007) Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis; 7: 481-490.
66. Lin P.L., Coleman T., Carney J.P., Lopresti B.J., Tomko J., Fillmore D., Dartois V., Scanga C., Frye L.J., Janssen C., Klein E., Barry C.E. III, Flynn J.L., (2013) Radiologic responses in cynomolgus macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother; 57: 4237-4244.
67. Bloom C.I., Graham C.M., Berry M.P., Rozakeas F., Redford P.S., Wang Y., Xu Z., et al,. (2013) Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE; 8: e70630.
68. Peterson E.J., Reiss D.J., Turkarslan S., Minch K.J., Rustad T., Plaisier C.L., Longabaugh W.J., Sherman D.R., Baliga N.S., (2015) A high-resolution network model for global gene regulation in Mycobacterium tuberculosis. Nucleic Acids Res; 42: 11291-11303.
69. Honeyborne I., McHugh T.D., Phillips P.P., Bannoo S., Bateson A., Carroll N., Perrin F.M., Ronacher K., Wright L., van Helden P.D., Walzl G., Gillespie S.H., (2011) Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol; 49: 3905-3911.
70. Kayigire X.A., Friedrich S.O., Venter A., Dawson R., Gillespie S.H., Boeree M.J., Heinrich N., Hoelscher M., Diacon A.H., (2013) Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol; 51: 1894-1898.
71. Honeyborne I., Mtafya B., Phillips P.P., Hoelscher M., Ntinginya E.N., Kohlenberg A., Rachow A., Rojas-Ponce G., McHugh T.D., Heinrich N., (2014) The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J Clin Microbiol; 52: 3064-3067.
72. Pethe K., Bifani P., Jang J., Kang S., Park S., Ahn S., Jiricek J., et al,. (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med; 19: 1157-1160.
73. Guzman J.D., Evangelopoulos D., Gupta A., Birchall K., Mwaigwisya S., Saxty B., McHugh T.D., Gibbons S., Malkinson J., Bhakta S., (2013) Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open; 3: e002672.
74. Gold B., Pingle M., Brickner S.J., Shah N., Roberts J., Rundell M., Bracken W.C., et al,. (2012) Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci USA; 109: 16004-16011.
75. Boshoff H.I., Myers T.G., Copp B.R., McNeil M.R., Wilson M.A., Barry C.E. III, (2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem; 279: 40174-40184.
76. Murima P., Sessions P.F.D., Lim V., Naim A.N.M., Bifani P., Boshoff H.I.M., Sambandamurthy V.K., Dick T., Hibberd M.L., Schreiber M., Rao S.P.S., (2013) Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in Mycobacteria. PLoS ONE; 8: e69191.
77. Koul A., Vranckx L., Dhar N., Gohlmann H.W., Ozdemir E., Neefs J.M., Schulz M., Lu P., Mortz E., McKinney J.D., Andries K., Bald D., (2014) Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun; 5: 3369.
78. Turapov O., Glenn S., Kana B., Makarov V., Andrew P.W., Mukamolova G.V., (2014) The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria. Am J Respir Crit Care Med; 190: 1455-1457.
79. Bloom C.I., Graham C.M., Berry M.P., Wilkinson K.A., Oni T., Rozakeas F., Xu Z., Rossello-Urgell J., Chaussabel D., Banchereau J., Pascual V., Lipman M., Wilkinson R.J., O'Garra A., (2012) Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE; 7: e46191.
80. Andreu N., Zelmer A., Sampson S.L., Ikeh M., Bancroft G.J., Schaible U.E., Wiles S., Robertson B.D., (2013) Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. J Antimicrob Chemother; 68: 2118-2127.
81. Bagci U., Foster B., Miller-Jaster K., Luna B., Dey B., Bishai W.R., Jonsson C.B., Jain S., Mollura D.J., (2013) A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res; 3: 55.
82. Manina G., Dhar N., McKinney J.D., (2015) Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe; 17: 32-46.
83. Dartois V., (2014) The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Micro; 12: 159-167.
84. Ashburn T.T., Thor K.B., (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov; 3: 673-683.
85. Palomino J.C., Martin A., (2013) Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother; 68: 275-283.